EASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data were presented comparing Eli…
Analyst Comment
EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis
EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2D
China expands its manufacturing role for biopharma’s new drugs
FDA hearing: psychedelics launch needs balanced regulation without limiting access
Looking beyond short-term turmoil, Syngene is investing for the future
ERS 2026: obesity, an independent obstruction to biologic-treated asthma
ERS 2026: BMI, type-2 inflammation, and asthma attack risk
